Abstract
NK cell cancer immunotherapy is an emerging anti-tumour therapeutic strategy that explores NK cell stimulation. In this review, we address strategies developed to circumvent limitations to clinical application of NK cell-based therapies, and comprehensively review the design and results of clinical trials conducted in the past 10 years (2008–2018) to test their therapeutic potential. NK cell-based immunotherapy of solid cancers remains controversial, but merit further detailed investigation.
Acknowledgements
We would like to thank Dr Cristina Pina, from Department of Haematology at University of Cambridge, for reading and editing the manuscript.
Disclosure statement
The authors have no commercial, proprietary, or financial interest in the products or companies described in this article. The research was made possible by resources donated by Lui Che Woo Foundation Limited.